ZP5461

ZP5461 is a novel, long-acting dual amylin and calcitonin receptor agonist developed for the treatment of obesity. It is a peptide-based drug that mimics the effects of the endogenous hormone amylin, which reduces food intake and body weight. Preclinical studies in both chow-fed and high-fat diet-fed rats have demonstrated that ZP5461 potently suppresses food intake and weight gain, with effects lasting up to 72 hours after a single injection. The mechanism of action involves activation of both amylin receptor and calcitonin receptor, particularly within the dorsal vagal complex (DVC) of the hindbrain—a key site for energy balance regulation. Chronic administration initially reduces energy intake and body weight gain; however, sustained suppression may require alternative dosing regimens. ZP5461 was developed by Zealand Pharma as part of their research into anti-obesity pharmacotherapies[1][2][3][4][5].